Revvity (RVTY) Competitors

Revvity has higher revenue and earnings than Bio-Techne. Revvity is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Bio-Techne currently has a consensus price target of $68.92, indicating a potential downside of 4.70%. Revvity has a consensus price target of $108.36, indicating a potential downside of 13.23%. Given Bio-Techne's higher possible upside, equities analysts clearly believe Bio-Techne is more favorable than Revvity.

Bio-Techne has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Revvity has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bio-Techne has a net margin of 14.97% compared to Revvity's net margin of 8.16%. Bio-Techne's return on equity of 13.23% beat Revvity's return on equity.

Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Revvity pays out 13.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Bio-Techne had 6 more articles in the media than Revvity. MarketBeat recorded 15 mentions for Bio-Techne and 9 mentions for Revvity. Bio-Techne's average media sentiment score of 1.20 beat Revvity's score of 1.18 indicating that Bio-Techne is being referred to more favorably in the media.

Agilent Technologies has higher revenue and earnings than Revvity. Agilent Technologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.6%. Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Agilent Technologies pays out 20.5% of its earnings in the form of a dividend. Revvity pays out 13.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

86.7% of Revvity shares are held by institutional investors. 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Agilent Technologies has a net margin of 19.55% compared to Revvity's net margin of 8.16%. Agilent Technologies' return on equity of 24.33% beat Revvity's return on equity.

In the previous week, Agilent Technologies had 23 more articles in the media than Revvity. MarketBeat recorded 32 mentions for Agilent Technologies and 9 mentions for Revvity. Agilent Technologies' average media sentiment score of 1.36 beat Revvity's score of 1.18 indicating that Agilent Technologies is being referred to more favorably in the media.

Agilent Technologies presently has a consensus target price of $160.24, suggesting a potential upside of 0.62%. Revvity has a consensus target price of $108.36, suggesting a potential downside of 13.23%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Agilent Technologies is more favorable than Revvity.

Agilent Technologies has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, Revvity has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bio-Rad Laboratories presently has a consensus price target of $343.33, suggesting a potential downside of 10.02%. Revvity has a consensus price target of $108.36, suggesting a potential downside of 13.23%. Given Bio-Rad Laboratories' higher possible upside, research analysts plainly believe Bio-Rad Laboratories is more favorable than Revvity.

Bio-Rad Laboratories has higher earnings, but lower revenue than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Bio-Rad Laboratories has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Revvity has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

In the previous week, Revvity had 5 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for Revvity and 4 mentions for Bio-Rad Laboratories. Revvity's average media sentiment score of 1.18 beat Bio-Rad Laboratories' score of 0.72 indicating that Revvity is being referred to more favorably in the news media.

Bio-Rad Laboratories has a net margin of 8.59% compared to Revvity's net margin of 8.16%. Revvity's return on equity of 8.34% beat Bio-Rad Laboratories' return on equity.

Revvity presently has a consensus price target of $108.36, suggesting a potential downside of 13.23%. Charles River Laboratories International has a consensus price target of $255.65, suggesting a potential downside of 13.41%. Given Revvity's higher probable upside, equities analysts plainly believe Revvity is more favorable than Charles River Laboratories International.

In the previous week, Charles River Laboratories International had 1 more articles in the media than Revvity. MarketBeat recorded 10 mentions for Charles River Laboratories International and 9 mentions for Revvity. Revvity's average media sentiment score of 1.18 beat Charles River Laboratories International's score of 0.53 indicating that Revvity is being referred to more favorably in the media.

Revvity has a net margin of 8.16% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Revvity's return on equity.

Revvity has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

86.7% of Revvity shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Revvity has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.